Medpage Today on MSN16h
Gene-Editing Therapy Reduced Attacks in Hereditary AngioedemaA single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in ...
Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
A single treatment with, a CRISPR-Cas9-based gene editing therapy, is enough to replace the daily medication of patients with ...
Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...
Pharmaceuticals announced new real-world comparative research on the use of oral, once-daily ORLADEYO that found high rates of ...
The company also announced new real-world evidence showing statistically significant and sustained HAE attack rate reductions after initiating ORLADEYO in patients with HAE, regardless of their ...
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing ...
For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback